Printer Friendly

ALTEON ANNOUNCES NEW RESEARCH AND DEVELOPMENT HEAD

 ALTEON ANNOUNCES NEW RESEARCH AND DEVELOPMENT HEAD
 NORTHVALE, N.J., Sept. 16 /PRNewswire/ -- Alteon Inc. (NASDAQ: ALTN)


today announced the appointment of Jere E. Goyan, Ph.D., as senior vice president research and development. Dr. Goyan has been a consultant to Alteon and a member of its Scientific Advisory Board since February 1989. He will now increase his consulting activities with the company before taking up this new full-time assignment officially on Jan. 4.
 Dr. Goyan is currently Professor of Pharmacy and Pharmaceutical Chemistry and Dean of the School of Pharmacy, University of California, San Francisco ("UCSF"). He is a former commissioner of food and drugs of the United States Food and Drug Administration.
 "This appointment substantially strengthens the company's research and development organization internally and will enhance our collaborative efforts with The Picower Institute for Medical Research and our corporate strategic partners, Yamanouchi and Marion Merrell Dow," said Charles A. Faden, Alteon's chairman, president and chief executive officer.
 Dr. Goyan is past president of the American Association of Pharmaceutical Scientists, a member of the Institute of Medicine of the National Academy of Sciences and a member of the Pew Health Professions Commission. He is a fellow of the American Association for the Advancement of Science, and the Academy of Pharmaceutical Research and Science. He is a member of Rho Chi Society, Phi Lambda Upsilon and Sigma Xi, and is the recipient of honorary doctoral degrees from several universities. He is the 1992 recipient of the Remington Honor Medal, the pharmacy profession's most distinguished award.
 Dr. Goyan's research interests have been in the physical chemistry of dosage form design. He has served on numerous committees relative to his research interests, pharmacy education and drug regulation. In addition, he has been very close to the pharmaceutical industry throughout his career and has served as consultant to numerous pharmaceutical and biotechnology companies.
 Dr. Goyan received his Ph.D. in pharmaceutical chemistry from the University of California, Berkeley and his B.S. in pharmacy from UCSF. From 1956 to 1963, he taught in the College of Pharmacy at the University of Michigan and has been on the faculty of the School of Pharmacy at UCSF since 1963.
 Alteon is a development stage pharmaceutical company engaged in the discovery and development of products for the treatment of the complications of diabetes and aging.
 -0- 9/16/92
 /CONTACT: Charles A. Faden, president and CEO of Alteon, 201-784-1010; or Susan Noonan of Noonan/Russo Communications, 212-979-9180, for Alteon/
 (ALTN) CO: Alteon Inc. ST: New Jersey IN: MTC SU: PER


GK-OS -- NY009 -- 9984 09/16/92 09:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1992
Words:433
Previous Article:OPTICAL SENSORS FOR MEDICINE HIRES THREE SCIENTISTS FOR RESEARCH AND DEVELOPMENT POSITIONS
Next Article:BANKATLANTIC INCREASES 1992 EARNINGS ESTIMATE 119 PERCENT
Topics:


Related Articles
ALTEON AND MARION MERRELL DOW EXPAND COLLABORATION ON DRUGS FOR DIABETES AND AGING
ALTEON ANNOUNCES NEW RESEARCH AND DEVELOPMENT HEAD
ALTEON CEO ANNOUNCES RETIREMENT
ALTEON CFO ANNOUNCES DEPARTURE
ALTEON INC. APPOINTS FORMER BRISTOL-MYERS SQUIBB EXECUTIVE JAMES J. MAUZEY AS CHIEF EXECUTIVE OFFICER
ALTEON INC. APPOINTS FRANK SPIEGEL TO BOARD OF DIRECTORS
ALTEON NAMES KENNETH I. MOCH SENIOR VICE PRESIDENT, FINANCE AND BUSINESS DEVELOPMENT AND CFO
ALTEON APPOINTS ROBERT N. BUTLER TO BOARD OF DIRECTORS
Alteon Appoints Dave McCurdy to Board of Directors
Alteon and Genentech to Collaborate on Therapy for Diabetic Complications

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters